{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["24(7)"],"submitter":["Tschirner SK"],"pubmed_abstract":["The β-secretase β-site APP cleaving enzyme 1 (BACE1) is a major drug target for Alzheimer's disease (AD). Clinically tested BACE1 inhibitors induced unexpected cognitive side effects that may stem from their cross-inhibition of the homologous protease BACE2. Yet, little is known about BACE2 functions and substrates in vivo, and no biomarker is available to monitor the extent of BACE2 inhibition in vivo, particularly in cerebrospinal fluid (CSF). To identify a potential CSF biomarker for monitoring BACE2 activity, we analyzed the CSF proteome changes in non-human primates after treatment with a BACE1-selective inhibitor (a brain-targeted monoclonal antibody) in comparison to verubecestat, a clinically tested small-molecule drug inhibiting both BACE1 and BACE2. Acute treatment with either th"],"journal":["Molecular & cellular proteomics : MCP"],"pagination":["101012"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12280488"],"repository":["biostudies-literature"],"pubmed_title":["Soluble VCAM-1 May Serve as a Pharmacodynamic CSF Marker to Monitor BACE2 Activity in Non-Human Primates."],"pmcid":["PMC12280488"],"pubmed_authors":["Lichtenthaler SF","Nalbach K","Muller SA","Zuchero YJY","Lewcock JW","Kennedy ME","Getz JA","Tschirner SK"],"additional_accession":[]},"is_claimable":false,"name":"Soluble VCAM-1 May Serve as a Pharmacodynamic CSF Marker to Monitor BACE2 Activity in Non-Human Primates.","description":"The β-secretase β-site APP cleaving enzyme 1 (BACE1) is a major drug target for Alzheimer's disease (AD). Clinically tested BACE1 inhibitors induced unexpected cognitive side effects that may stem from their cross-inhibition of the homologous protease BACE2. Yet, little is known about BACE2 functions and substrates in vivo, and no biomarker is available to monitor the extent of BACE2 inhibition in vivo, particularly in cerebrospinal fluid (CSF). To identify a potential CSF biomarker for monitoring BACE2 activity, we analyzed the CSF proteome changes in non-human primates after treatment with a BACE1-selective inhibitor (a brain-targeted monoclonal antibody) in comparison to verubecestat, a clinically tested small-molecule drug inhibiting both BACE1 and BACE2. Acute treatment with either th","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jun","modification":"2026-03-27T15:51:21.857Z","creation":"2025-08-24T03:08:59.884Z"},"accession":"S-EPMC12280488","cross_references":{"pubmed":["40480341"],"doi":["10.1016/j.mcpro.2025.101012"]}}